Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
Condition: Early Breast Cancer Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide; Drug: Taxane; Drug: Letrozole; Drug: Abemaciclib; Drug: LHRH Analogue Sponsors: Spanish Breast Cancer Research Group; Eli Lilly and Company Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Study